CLAIMS


What is claimed is:

1. An oral dosage form comprising a therapeutically effective amount of compound A, lactose and low-substituted hydroxypropyl cellulose,

wherein said therapeutically effective amount is a single daily dose ranging from about 2.5 mg to about 10 mg;

wherein said dosage form provides a dissolution rate of 85 % or more in dissolution medium (0.1 mol/L hydrochloric acid containing 0.5% polysorbate 80, 900 mL, 37 ± 0.5°C) within 30 minutes from the onset of dissolution study using the Apparatus 2 (Paddle Apparatus, paddle speed; 75 rpm) according to the procedure for immediate-release dosage form in 6.10 Dissolution test of JP16 or <711> Dissolution of USP37; and

wherein said compound A is (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide represented by the following formula:



.

2. The dosage form of claim 1, wherein said dosage form provides a dissolution rate of 85 % or more in dissolution medium (0.1 mol/L hydrochloric acid, 900 mL, 37 ± 0.5°C) within 15 minutes from the onset of dissolution study using the Apparatus 2 (Paddle Apparatus, paddle speed; 50 rpm) according to the procedure for immediate-release dosage form in 6.10 Dissolution test of JP16 or <711> Dissolution of USP37.